<?xml version='1.0' encoding='utf-8'?>
<document id="25324279"><sentence text="Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone."><entity charOffset="130-140" id="DDI-PubMed.25324279.s1.e0" text="amiodarone" /></sentence><sentence text="Evaluation of drug-drug interaction (DDI) involving circulating inhibitory metabolites of perpetrator drugs has recently drawn more attention from regulatory agencies and pharmaceutical companies" /><sentence text=" Here, using amiodarone (AMIO) as an example, we demonstrate the use of physiologically based pharmacokinetic (PBPK) modeling to assess how a potential inhibitory metabolite can contribute to clinically significant DDIs"><entity charOffset="13-23" id="DDI-PubMed.25324279.s3.e0" text="amiodarone" /><entity charOffset="25-29" id="DDI-PubMed.25324279.s3.e1" text="AMIO" /><pair ddi="false" e1="DDI-PubMed.25324279.s3.e0" e2="DDI-PubMed.25324279.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25324279.s3.e0" e2="DDI-PubMed.25324279.s3.e1" /></sentence><sentence text=" Amiodarone was reported to increase the exposure of simvastatin, dextromethorphan, and warfarin by 1"><entity charOffset="1-11" id="DDI-PubMed.25324279.s4.e0" text="Amiodarone" /><entity charOffset="53-64" id="DDI-PubMed.25324279.s4.e1" text="simvastatin" /><entity charOffset="66-82" id="DDI-PubMed.25324279.s4.e2" text="dextromethorphan" /><entity charOffset="88-96" id="DDI-PubMed.25324279.s4.e3" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.25324279.s4.e0" e2="DDI-PubMed.25324279.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25324279.s4.e0" e2="DDI-PubMed.25324279.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25324279.s4.e0" e2="DDI-PubMed.25324279.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25324279.s4.e0" e2="DDI-PubMed.25324279.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25324279.s4.e1" e2="DDI-PubMed.25324279.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25324279.s4.e1" e2="DDI-PubMed.25324279.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25324279.s4.e1" e2="DDI-PubMed.25324279.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25324279.s4.e2" e2="DDI-PubMed.25324279.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25324279.s4.e2" e2="DDI-PubMed.25324279.s4.e3" /></sentence><sentence text="2- to 2-fold, which was not expected based on its weak inhibition observed in vitro" /><sentence text=" The major circulating metabolite, mono-desethyl-amiodarone (MDEA), was later identified to have a more potent inhibitory effect"><entity charOffset="35-59" id="DDI-PubMed.25324279.s6.e0" text="mono-desethyl-amiodarone" /><entity charOffset="61-65" id="DDI-PubMed.25324279.s6.e1" text="MDEA" /><pair ddi="false" e1="DDI-PubMed.25324279.s6.e0" e2="DDI-PubMed.25324279.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25324279.s6.e0" e2="DDI-PubMed.25324279.s6.e1" /></sentence><sentence text=" Using a combined &quot;bottom-up&quot; and &quot;top-down&quot; approach, a PBPK model was built to successfully simulate the pharmacokinetic profile of AMIO and MDEA, particularly their accumulation in plasma and liver after a long-term treatment"><entity charOffset="134-138" id="DDI-PubMed.25324279.s7.e0" text="AMIO" /><entity charOffset="143-146" id="DDI-PubMed.25324279.s7.e1" text="MDEA" /><pair ddi="false" e1="DDI-PubMed.25324279.s7.e0" e2="DDI-PubMed.25324279.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25324279.s7.e0" e2="DDI-PubMed.25324279.s7.e1" /></sentence><sentence text=" The clinical AMIO DDIs were predicted using the verified PBPK model with incorporation of cytochrome P450 inhibition from both AMIO and MDEA"><entity charOffset="128-132" id="DDI-PubMed.25324279.s8.e0" text="AMIO" /><entity charOffset="14-17" id="DDI-PubMed.25324279.s8.e1" text="AMIO" /><entity charOffset="137-140" id="DDI-PubMed.25324279.s8.e2" text="MDEA" /><pair ddi="false" e1="DDI-PubMed.25324279.s8.e1" e2="DDI-PubMed.25324279.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25324279.s8.e1" e2="DDI-PubMed.25324279.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25324279.s8.e1" e2="DDI-PubMed.25324279.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25324279.s8.e0" e2="DDI-PubMed.25324279.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25324279.s8.e0" e2="DDI-PubMed.25324279.s8.e2" /></sentence><sentence text=" The closest prediction was obtained for CYP3A (simvastatin) DDI when the competitive inhibition from both AMIO and MDEA was considered, for CYP2D6 (dextromethorphan) DDI when the competitive inhibition from AMIO and the competitive plus time-dependent inhibition from MDEA were incorporated, and for CYP2C9 (warfarin) DDI when the competitive plus time-dependent inhibition from AMIO and the competitive inhibition from MDEA were considered"><entity charOffset="48-59" id="DDI-PubMed.25324279.s9.e0" text="simvastatin" /><entity charOffset="107-111" id="DDI-PubMed.25324279.s9.e1" text="AMIO" /><entity charOffset="149-165" id="DDI-PubMed.25324279.s9.e2" text="dextromethorphan" /><entity charOffset="208-223" id="DDI-PubMed.25324279.s9.e3" text="AMIO" /><entity charOffset="380-395" id="DDI-PubMed.25324279.s9.e4" text="AMIO" /><entity charOffset="116-131" id="DDI-PubMed.25324279.s9.e5" text="MDEA" /><entity charOffset="269-284" id="DDI-PubMed.25324279.s9.e6" text="MDEA" /><entity charOffset="421-436" id="DDI-PubMed.25324279.s9.e7" text="MDEA" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e0" e2="DDI-PubMed.25324279.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e0" e2="DDI-PubMed.25324279.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e0" e2="DDI-PubMed.25324279.s9.e5" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e0" e2="DDI-PubMed.25324279.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e0" e2="DDI-PubMed.25324279.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e0" e2="DDI-PubMed.25324279.s9.e6" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e0" e2="DDI-PubMed.25324279.s9.e4" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e0" e2="DDI-PubMed.25324279.s9.e7" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e1" e2="DDI-PubMed.25324279.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e1" e2="DDI-PubMed.25324279.s9.e5" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e1" e2="DDI-PubMed.25324279.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e1" e2="DDI-PubMed.25324279.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e1" e2="DDI-PubMed.25324279.s9.e6" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e1" e2="DDI-PubMed.25324279.s9.e4" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e1" e2="DDI-PubMed.25324279.s9.e7" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e5" e2="DDI-PubMed.25324279.s9.e5" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e5" e2="DDI-PubMed.25324279.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e5" e2="DDI-PubMed.25324279.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e5" e2="DDI-PubMed.25324279.s9.e6" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e5" e2="DDI-PubMed.25324279.s9.e4" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e5" e2="DDI-PubMed.25324279.s9.e7" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e2" e2="DDI-PubMed.25324279.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e2" e2="DDI-PubMed.25324279.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e2" e2="DDI-PubMed.25324279.s9.e6" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e2" e2="DDI-PubMed.25324279.s9.e4" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e2" e2="DDI-PubMed.25324279.s9.e7" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e3" e2="DDI-PubMed.25324279.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e3" e2="DDI-PubMed.25324279.s9.e6" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e3" e2="DDI-PubMed.25324279.s9.e4" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e3" e2="DDI-PubMed.25324279.s9.e7" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e6" e2="DDI-PubMed.25324279.s9.e6" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e6" e2="DDI-PubMed.25324279.s9.e4" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e6" e2="DDI-PubMed.25324279.s9.e7" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e4" e2="DDI-PubMed.25324279.s9.e4" /><pair ddi="false" e1="DDI-PubMed.25324279.s9.e4" e2="DDI-PubMed.25324279.s9.e7" /></sentence><sentence text=" The PBPK model with the ability to simulate DDI by considering dynamic change and accumulation of inhibitor (parent and metabolite) concentration in plasma and liver provides advantages in understanding the possible mechanism of clinical DDIs involving inhibitory metabolites" /><sentence text=" " /></document>